Safiglipron
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
Shandong Suncadia Medicine Co · Phase 3 · Recruiting · Enrollment 648
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Treatment group A: HRS-7535 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group B: Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |